Immuno Oncology Assays Market Size (2024 - 2029)

The Immuno Oncology Assays Market is anticipated to experience significant growth, driven by the increasing incidence of cancer and the rising adoption of targeted therapies. The market's expansion is supported by substantial investments in research and development by government and pharmaceutical entities, which facilitate advancements in assay methods and products. Despite the challenges posed by stringent refund policies, the market is poised for growth due to new product approvals and launches. The post-pandemic recovery has also contributed to the market's positive trajectory, as healthcare services resume and cancer screening activities are revitalized.

Market Size of Immuno Oncology Assays Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Immuno Oncology Assays Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 12.30 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Immuno Oncology Assays Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Immuno Oncology Assays Market Analysis

The Immuno Oncology Assays Market is expected to register a CAGR of 12.3% over the forecast period.

Cancer patients have faced significant complications due to the 2019 coronavirus disease (COVID-19). The COVID-19 pandemic's breakout has severely impacted the global healthcare supply chain. Also, the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed. The only exception is if the risks have outweighed the benefits and secure the hospital infrastructure to treat COVID-19 patients. Thus, the COVID-19 pandemic has impacted the market. However, the situation has improved over the post-pandemic era gradually.

Immuno-oncology studies and develops treatments that utilize the body's immune system to fight cancer. The primary factor contributing to the market's growth is the increase in cancer incidence. According to the ECIS, the European cancer burden is expected to reach 3.36 million new cases by 2040, compared to 2.94 million patients in 2025. Furthermore, the increasing adoption of targeted therapy is boosting market growth. Immuno-oncology assays measure the concentration of the therapeutic antibody, anti-drug antibodies, and soluble protein biomarkers. As targeted therapy popularity increases, the assays' market growth increases.

Additionally, some primary factors driving the regional market are high expenditure on R&D by government organizations and pharmaceutical companies for disorders and diseases, such as chronic ailments like cancers. For instance, as per PhRMA, the biopharmaceutical industry invested an estimated USD 102,288 million in research and development (R&D) in 2021. Thus the significant funding for R&D helps the market to grow through new developments in immune-oncology assays.

Moreover, the new developments and advancements in assay methods and products, along with the approvals and launches, help the market to grow. For instance, in April 2022, Agilent Technologies Inc. received a CE-IVD marking in the European Union for its PD-L1 IHC 28-8 pharmDx immunohistochemical assay. It tests patients diagnosed with muscle-invasive urothelial carcinoma (MIUC) and tumor cell PD-L1 expression 1% for adjuvant treatment with OPDIVO (nivolumab). Similarly, in October 2021, the same company, Agilent, received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers. Hence, with the new approvals and launches, the increase in cancer incidence and R&D expenditure is expected to drive the market over the forecast period.

However, stringent and unfavorable refund policies are hindering market growth factors.

Immuno Oncology Assays Industry Segmentation

As per the scope of the report, Immuno oncology assays is a next-generation sequencing application that delivers real-time automated measurements of immune and tumor cell dynamics. With the help of this assay, people can analyze biological processes driving the immune response against cancer. It helps continuously examine and analyze key events from proliferation and activation to migration and immune cell killing without disturbing the existing body cells. The Immuno Oncology Assays Market is segmented by product (reagents and antibodies, instruments, software and consumables, and accessories), technology (immunoassay, PCR, NGS, Flow Cytometry, and other technologies), indication (lung cancer, colorectal cancer, Melanoma, and other cancers) and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value in (USD million) for the above segments.

By Product
Reagents and Antibodies
Instruments
Software
Consumables and Accessories
By Technology
Immunoassay
PCR
NGS
Flow Cytometry
Other Technologies
By Indication
Lung Cancer
Colorectal Cancer
Melanoma
Other Cancers
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Immuno Oncology Assays Market Size Summary

The Immuno Oncology Assays Market is poised for significant growth, driven by the increasing incidence of cancer and the rising adoption of targeted therapies. This market focuses on developing treatments that harness the body's immune system to combat cancer, with assays playing a crucial role in measuring therapeutic antibodies and biomarkers. The market's expansion is supported by substantial investments in research and development by government bodies and pharmaceutical companies, which facilitate advancements in assay methods and products. Despite the challenges posed by the COVID-19 pandemic, which disrupted healthcare services and supply chains, the market has shown resilience and is expected to continue its upward trajectory over the forecast period.

Regionally, North America is anticipated to experience robust growth due to its established healthcare infrastructure, high cancer prevalence, and the presence of key industry players. The market benefits from favorable government initiatives and research collaborations that bolster its development. The introduction of new products and approvals, such as those by Agilent Technologies and Thermo Fisher Scientific, further propels market growth by expanding the scope of immune-oncology assays. However, the market faces challenges from stringent reimbursement policies, which could impede its growth. Overall, the Immuno Oncology Assays Market is moderately competitive, with major players like Agilent Technologies, Thermo Fisher Scientific, and Illumina leading the charge in innovation and market share.

Explore More

Immuno Oncology Assays Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Incidence of Cancer Globally

      2. 1.2.2 Increasing Adoption of Targeted Therapy

    3. 1.3 Market Restraints

      1. 1.3.1 Unfavorable Regulatory and Reimbursement Scenario

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Product

      1. 2.1.1 Reagents and Antibodies

      2. 2.1.2 Instruments

      3. 2.1.3 Software

      4. 2.1.4 Consumables and Accessories

    2. 2.2 By Technology

      1. 2.2.1 Immunoassay

      2. 2.2.2 PCR

      3. 2.2.3 NGS

      4. 2.2.4 Flow Cytometry

      5. 2.2.5 Other Technologies

    3. 2.3 By Indication

      1. 2.3.1 Lung Cancer

      2. 2.3.2 Colorectal Cancer

      3. 2.3.3 Melanoma

      4. 2.3.4 Other Cancers

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Immuno Oncology Assays Market Size FAQs

The Immuno Oncology Assays Market is projected to register a CAGR of 12.30% during the forecast period (2024-2029)

Agilent Technologies, Inc, Thermo Fisher Scientific, Illumina, Inc., PerkinElmer, Inc. and Crown Bioscience are the major companies operating in the Immuno Oncology Assays Market.

Immuno Oncology Assays Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)